Financials data is unavailable for this security.
View more
Year on year Shandong Pharmaceutical Glass Co Ltd grew revenues 18.98% from 4.19bn to 4.98bn while net income improved 25.48% from 618.29m to 775.80m.
Gross margin | 29.71% |
---|---|
Net profit margin | 16.82% |
Operating margin | 20.10% |
Return on assets | 9.13% |
---|---|
Return on equity | 11.62% |
Return on investment | 11.53% |
More ▼
Cash flow in CNYView more
In 2023, Shandong Pharmaceutical Glass Co Ltd increased its cash reserves by 10.90%, or 126.48m. The company earned 1.05bn from its operations for a Cash Flow Margin of 21.03%. In addition the company used 744.57m on investing activities and also paid 186.62m in financing cash flows.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 11.67 |
---|---|
Tangible book value per share | 11.29 |
More ▼
Balance sheet in CNYView more
Current ratio | 2.87 |
---|---|
Quick ratio | 2.35 |
Total debt/total equity | 0.0913 |
---|---|
Total debt/total capital | 0.0837 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 33.33% and 25.48%, respectively. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg) | 1.00% |
---|---|
Div growth rate (5 year) | 13.30% |
Payout ratio (TTM) | 53.67% |
EPS growth(5 years) | 14.19 |
---|---|
EPS (TTM) vs TTM 1 year ago | 23.31 |
More ▼